Trading is looking strong for some of the pharmaceutical firms this morning, but the FTSE 100 is str...
Trading is looking strong for some of the pharmaceutical firms this morning, but the FTSE 100 is struggling to make the best of it so far thanks to Barclays.
The benchmark FTSE 100 is down just a fraction at 3926, having climbed made its biggest monthly gain since in April and risen 8.7%.
Barclays has already lost 2.4% to 432.25p while Lloyds TSB Group, has dropped 2.4% to 411.5p.
At the other end of the spectrum, Amersham, which makes medical tools, has climbed 27.75p or 6.6% to 449.25p as first quarter is little changed on last year's £381m.
AstraZeneca is also up 79p or 3.3% to £24.55, even though its Q1 profit fell 2.7% to $932m - but this is still around £200m higher than most analysts were expecting.
GlaxoSmithKline has added 25p or 2% to £12.54 after first-quarter net income rose 17% to £1.19bn billion pounds, boosted by sales of the asthma treatment Advair.
And despite predictions of falling profits for travel firms, First Choice Holidays has risen 5p or 5.6% to 94p this morning as the firm is reported to be trading as expected.
In the US yesterday, the Dow Jones closed down 22.9 points or 0.27% to 8,480.9 while the Nasdaq lost 6.99 points or 0.48% to 1, 464.31 and the S&P 500 index closed relatively flat as it lost just 0.92 points or 0.1% to 916.92.
Activity was relatively quiet in Asia today, given that most countries are enjoying a bank holiday. IN Japan, stocks climbed 0.1% to 7837.09 after one of its newspapers revealed Sumitomo Mitsui Financial Groupis being urged by ruling coalition parties to buy bank shares and help support the stock market.
To cost £36bn by 2060/61
Banned for a total of 34 years
Self-administered pensions reported net investment £4.7bn in Q2
Was responsible for IT and transformation
There are 1,840 asset management firms with £8trn AUM